Related Experiment Video
Updated: Aug 13, 2025
09:29
Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
Published on: January 9, 2015
15.5K
Identifying the Basic Dimensions of Medication-Triggered Impulsive Compulsive Behaviours in Parkinson's Disease
Nicky Edelstyn1, Elisa Di Rosa2, Alice Martini1
1School of Psychology, Keele University, Staffordshire, UK.
European Neurology
|January 19, 2023
Summary
Parkinson's disease patients with impulsive-compulsive behaviors (ICBs) show abnormal striatal dopamine function and reduced fronto-striatal connectivity. These neurobiological changes correlate with cognitive and emotional deficits, offering potential markers for ICBs.
Area of Science:
- Neuroscience
- Psychiatry
- Movement Disorders
Background:
- Impulsive-compulsive behaviors (ICBs) are distressing in Parkinson's disease (PD).
- Identifying reliable markers for ICBs is crucial for early diagnosis and treatment.
- This review integrates behavioral and neuroimaging data to find correlates of ICBs in PD.
Purpose of the Study:
- To identify basic correlates of impulsive-compulsive behaviors (ICBs) in Parkinson's disease (PD).
- To determine reliable markers of ICBs across multiple levels of analysis.
- To guide future research on the mechanisms underlying ICBs in PD.
Main Methods:
- Systematic review of published behavioral and neuroimaging studies.
- Analysis of dopamine metabolism in the striatum.
- Assessment of functional magnetic resonance imaging (fMRI) data.
- Cognitive, affective, and motivational assessments in PD patients with and without ICBs.
Main Results:
- Patients with ICBs (ICB+) exhibit abnormal striatal dopamine function and altered reward processing networks.
- Reduced fronto-striatal connectivity is observed in ICB+ patients.
- Findings align with psychological dysfunction, including impaired cognitive control, altered reward-based decision-making, and increased negative affect.
Conclusions:
- Convergent findings suggest neurobiological and psychological underpinnings of ICBs in PD.
- Further research is needed to understand mechanisms increasing vulnerability to ICBs.
- Identifying reliable ICB markers is essential for clinical utility and therapeutic trials in PD.
Related Concept Videos
01:24Parkinson's Disease: Treatment
331
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
331
01:15Parkinson's Disease: Overview
644
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
644
01:28Obsessive-Compulsive Disorder
180
Obsessive-compulsive disorder (OCD) is a mental health condition characterized by recurrent obsessions, compulsions, or both, which consume significant time and interfere with daily functioning. Obsessions involve persistent, intrusive, and unwanted thoughts, images, or urges that evoke anxiety. Common examples include irrational fears of contamination or harm. Compulsions are repetitive behaviors or mental acts performed to reduce the anxiety caused by obsessions. For instance, individuals...
180
01:28Drug Therapy
83
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
83
01:26Psychosis: Goals of Pharmacotherapy
185
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
185
01:15Drug Abuse and Addiction: Pharmacological Phenomena
601
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
601